Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases.

Détails

ID Serval
serval:BIB_C4DDFE5880FE
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases.
Périodique
Cancer treatment reviews
Auteur⸱e⸱s
Zimmermann Stefan, Dziadziuszko R., Peters S.
ISSN
1532-1967 (Electronic)
ISSN-L
0305-7372
Statut éditorial
Publié
Date de publication
07/2014
Peer-reviewed
Oui
Volume
40
Numéro
6
Pages
716-722
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Lung cancer is characterized by the highest incidence of solid tumor-related brain metastases, which are reported with a growing incidence during the last decade. Prognostic assessment may help to identify subgroups of patients that could benefit from more aggressive therapy of metastatic disease, in particular when central nervous system is involved. The recent sub-classification of non-small cell lung cancer (NSCLC) into molecularly-defined "oncogene-addicted" tumors, the emergence of effective targeted treatments in molecularly defined patient subsets, global improvement of advanced NSCLC survival as well as the availability of refined new radiotherapy techniques are likely to impact on outcomes of patients with brain dissemination. The present review focuses on key evidence and research strategies for systemic treatment of patients with central nervous system involvement in non-small cell lung cancer.
Mots-clé
Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Blood-Brain Barrier, Brain Neoplasms/drug therapy, Brain Neoplasms/secondary, Brain Neoplasms/surgery, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/secondary, Carcinoma, Non-Small-Cell Lung/surgery, Erlotinib Hydrochloride, Humans, Incidence, Lung Neoplasms/pathology, Molecular Targeted Therapy/methods, Prognosis, Quinazolines/administration & dosage, Radiosurgery, Receptor, Epidermal Growth Factor/drug effects, Receptor, Epidermal Growth Factor/genetics, Treatment Outcome, Brain metastasis, Driver oncogenes, Non small cell lung cancer (NSCLC), Stereotactic radiotherapy, Targeted treatment
Pubmed
Web of science
Création de la notice
13/06/2018 8:14
Dernière modification de la notice
21/08/2019 5:37
Données d'usage